---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-26-000026"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:46:55.895536+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance

## Summary
- Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).
- Adjusted EBITDA $23.9M (+24% from $19.2M); cash from ops $8.9M vs -$19.3M.
- Pain Treatments +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%; International +17.1%.
- Raised FY26 Adj EPS guidance to $0.75-$0.79 (up $0.02), CFO to $84-$89M (up $2M); reaffirms rev $600-610M.
- Discretionary $22M term loan prepayment on Mar 27 reduces debt and future interest.

## SEC filing metadata
- accession: 0001665988-26-000026
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/bvs-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-26-000026
- JSON: https://secwatch.observer/filing/0001665988-26-000026.json
- Plain text: https://secwatch.observer/filing/0001665988-26-000026.txt

## Source-grounded claims
- claim_id: 3f38ebbc252b120765987fbaeba43a22e2abd456
  claim: Bioventus Inc. reported three months ended March 28, 2026 results: revenue $132.1 million, net income $3.1 million, EPS $0.04 per diluted share. Guidance raised.
  evidence_excerpt: For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.